Fate Therapeutics (FATE) Stock Forecast, Price & News

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.

21 brokers have issued 1 year target prices for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 195.2% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.

Fate Therapeutics' stock was trading at $10.09 at the beginning of 2023. Since then, FATE stock has decreased by 48.0% and is now trading at $5.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our FATE earnings forecast.

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.36. The biopharmaceutical company had revenue of $58.98 million for the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 45.62% and a negative net margin of 171.64%. The firm's revenue was up 220.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.68) earnings per share.

ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Vanguard Russell 2000 Growth ETF (VTWG) and Principal Healthcare Innovators ETF (BTEC).

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (15.07%), BlackRock Inc. (11.66%), Bank of America Corp DE (2.19%), Two Sigma Advisers LP (1.90%), Two Sigma Investments LP (1.83%) and JPMorgan Chase & Co. (1.75%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FATE stock can currently be purchased for approximately $5.25.

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $516.50 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

The company employs 449 workers across the globe.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.